GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits
Wednesday, July 15 – (MedPage Today) — Note that some links may require registration or subscription.
A cohort study found that diabetes patients taking GLP-1 receptor agonists had a higher risk of anterior ischemic optic neuropathy, a potentially blinding eye condition…
Popular weight-loss drugs Ozempic and Wegovy may slow biological aging
Wednesday, July 15 – Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging. Although the findings are encouraging, scientists say larger studies are needed before concluding that the medication can help people age more slowly.
Study Dampens Hope for GLP-1s as Insulin Off-Ramp in Type 2 Diabetes
(Wednesday, July 15 – MedPage Today) — Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation trial…
Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread
Wednesday, July 15 – In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere—from NPR and The Washington Post to Substack and heated exchanges on social media—all circling the same claim: Ozempic might lower the risk of cancer.
China’s Mindrank raises $52M series B to advance oral GLP-1
Wednesday, July 15 – Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.
How GLP-1 drugs like Ozempic could help prevent lung scarring after COVID
Monday, July 13 – How GLP-1 drugs like Ozempic could help prevent lung scarring after COVID
Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial
Monday, July 13 – Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes. The study included adults with Type 2 diabetes who were not taking diabetes medicines and whose blood sugar was not adequately controlled with diet and exercise alone.
If A GLP-1 Medication Has Changed Your Life For The Better, We Want To Hear About It
Sunday, July 12 – Whether it’s been about weight, blood sugar, PCOS, food noise, or something else entirely, we want to hear.View Entire Post ›
Study Compares GLP-1 Drugs on Their Benefits, Harms
Sunday, July 12 – (MedPage Today) — Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear.
Across 262 randomized studies published through November…
Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk
Friday, July 10 – (MedPage Today) — Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of antidiabetic medications.
Rates of new-onset autoimmune conditions were compared…